Indian generic HIV antiretrovirals (2001)
Cipla, an Indian pharmaceutical company, offered a triple-combination antiretroviral therapy for less than $1 per day—compared to the roughly $15,000 per year charged by Western manufacturers. Cipla's founder, Yusuf Hamied, announced the price at a European Commission conference, triggering a global access revolution. By 2008, Indian-manufactured generic antiretrovirals supplied 87% of donor-funded purchases in developing countries, reaching 96 nations.
Drug prices in Africa fell to roughly $200 per patient per year within four years. Millions of people who would have died gained access to life-saving treatment.
India cemented its role as the 'pharmacy of the world' for generic medicines. The episode shaped global norms around compulsory licensing, voluntary licensing agreements, and the balance between patent protection and public health access.
India's generic semaglutide launch follows the same structural pattern: a life-changing drug priced beyond the reach of most patients in developing countries, followed by an explosion of Indian generic competition that drops prices by 90% or more. The question is whether GLP-1 generics will replicate the antiretroviral model's global reach.